Will Roche (RHHBY) Stock Be Helped By Santaris Pharma Acquisition?

NEW YORK (TheStreet) -- Roche Holding (RHHBY) said it will buy Santaris Pharma, a privately-held Danish biotech company, for up to $450 million in cash, according to Reuters.

Santaris develops drugs to fight liver cancer, head and neck cancer, and against metabolic and infectious diseases.

It is partly owned by Danish venture capital firm Sunstone, which earlier this year considered a U.S. listing for the company, Reuters said. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shares of Roche Holding are down -0.79% to $35.98.

RHHBY ChartRHHBY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech